欧盟 - 英文 - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

elanco gmbh - inactivated mycoplasma hyopneumoniae (strain p-5722-3) - emulsion for injection - . - mycoplasma

澳大利亚 - 英文 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - mycoplasma hyopneumoniae - inactivated antigen; cpcv 1-2 inactivated suspension; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 1.0 rp; cpcv 1-2 inactivated suspension vaccine-virus active 1.0 rp; thiomersal mercury other 0.1 mg/ml - immunotherapy

比利时 - 英文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

elanco - mycoplasma hyopneumoniae (inactivated) min. 6000 ur/dose - emulsion for injection - mycoplasma hyopneumoniae, inactivated - mycoplasma - pig

欧盟 - 英文 - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

菲律宾 - 英文 - FDA (Food And Drug Administration)

zoetis philippines, inc.; distributor: zoetis philippines, inc. - inactivated mycoplasma hyopneumoniae bacterin - emulsion for injection (im) - formulation: each 2 ml contains: mycoplasma hyopneumoniae bacterin - p-5722-3 strain (nl 1042) ............. 25.06 x 108 ccu

菲律宾 - 英文 - FDA (Food And Drug Administration)

ceva animal health (philippines), inc.; distributor: ceva animal health (philippines), inc. - inactivated mycoplasma hyopneumoniae vaccine (vet.) - emulsion for injection (im) - formulation: each 2 ml (dose) contains: mycoplasma hyopneumoniae (2940 strain).............................>2.75 elisa units enzyme-linked immunosorbent assay (elisa)

欧盟 - 英文 - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals for suidae - pigs (for fattening) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d.active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - inactivated mycoplasma hyopneumoniae, inactivated haemophilus parasuis serovar 4, inactivated haemophilus parasuis serovar 5 - suspension for injection - unknown - mycoplasma vaccine + haemophilus vaccine - porcine - immunological - inactivated vaccine

欧盟 - 英文 - EMA (European Medicines Agency)

intervet international b.v. - porcine circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j strain inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs (for fattening) - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (pcv2) infection, and severity of lung lesions caused by mycoplasma hyopneumoniae infection. to reduce the loss of daily weight gain during the finishing period in face of infections with mycoplasma hyopneumoniae and/or pcv2 (as observed in field studies)